by Alison Bass | Aug 7, 2012 | antidepressants, clinical trials, National Institutes of Health, pharmaceutical industry, scientific journal retractions, scientific misconduct, university industry collaboration
The Chronicle of Higher Education this week ponders why various universities have taken no action against the academic researchers who co-authored the notorious Paxil study that formed the crux of GlaxoSmithKline’s recent $3 billion settlement with the...
by Alison Bass | Jul 3, 2012 | antidepressants, antipsychotic drugs, clinical trials, drug marketing, patient care, pharmaceutical industry, scientific journal retractions, scientific misconduct, suicide rates, whistleblowing
I was glad to see that the New York Times’ reporters covering GlaxoSmithKline’s $3 billion settlement tipped their hat to former New York Attorney General Eliot Spitzer. After all, it was his crew and specifically a pioneering attorney by the name of Rose...
by Alison Bass | May 8, 2012 | antidepressants, clinical trials, drug marketing, FDA, media coverage, National Institutes of Health, patient care, pharmaceutical industry, Uncategorized
Two weeks ago, I headlined my blog with this question: Is the FDA violating its own mandate to approve safe drugs? Four days later, the national Institute of Medicine (IOM) released a 233-page report concluding that FDA’s current approach to drug oversight “is...
by Alison Bass | Apr 27, 2012 | antidepressants, biotech industry, clinical trials, continuing medical education, drug marketing, FDA, health care costs, medical devices, patient care, pharmaceutical industry, scientific misconduct, suicide rates, Uncategorized
Is the Food and Drug Administration violating its own mandate to approve safe drugs? That was the question that Donald Light, co-author of The Risk for Prescription Drugs and a long-time medical sociologist, posed at a talk yesterday at Brandeis University. The...
by Alison Bass | Apr 12, 2012 | antidepressants, antipsychotic drugs, clinical trials, drug marketing, FDA, health care costs, patient care, pharmaceutical industry, scientific misconduct
I’ve been reading Dr. David Healy’s new book, Pharmageddon, and while some of it may seem like old news, I was struck by his fresh analysis of how the pharmaceutical industry has turned the original purpose of clinical trials inside out. As Healy, a noted...
by Alison Bass | Feb 20, 2012 | antidepressants, conflicts of interest, drug marketing, health care costs, pharmaceutical industry
When Dr. Irving Kirsch published his meta-analysis in PLoS Medicine in February 2008 showing that antidepressants were no more effective than a placebo in treating mild or moderate depression, the national news media ignored his explosive findings, for the most part....
